DIRS.INFO The most relevant business & tech news

☆ Tony Awards 2024: Print Your Ballot!
▼ + stars: | 2024-05-13 | by ( ) www.nytimes.com time to read: +5 min

Best New Play "Jaja's African Hair Braiding" ☐ "Mary Jane" ☐ "Mother Play" ☐ "Prayer for the French Republic" ☐ "Stereophonic" Best New Musical "Hell's Kitchen" “Illinoise" ☐ "The Outsiders" ☐ "Suffs" "Water for Elephants" Best Play Revival ☐ “Appropriate" ☐ “An Enemy of the People" "Purlie Victorious" Best Musical Revival ☐ "Cabaret" ☐ “Gutenberg! The Musical!" "Merrily We Roll Along" "The Who's Tommy" Best Book of a Musical ☐ Bekah Brunstetter, "The Notebook" Kristoffer Diaz, "Hell's Kitchen" ☐ Rick Elice, "Water for Elephants" ☐ Adam Rapp with Justin Levine, "The Outsiders" ☐ Shaina Taub, "Suffs" Best Leading Actor in a Play ☐ William Jackson Harper, "Uncle Vanya" Leslie Odom Jr., "Purlie Victorious" ☐ Liev Schreiber, "Doubt" Jeremy Strong, "An Enemy of the People" ☐ Michael Stuhlbarg, "Patriots" Best Leading Actress in a Play ☐ Betsy Aidem, "Prayer for the French Republic" 0000 Jessica Lange, "Mother Play" Rachel McAdams, "Mary Jane" Sarah Paulson, "Appropriate" ☐ Amy Ryan, "Doubt" Best Leading Actor in a Musical ☐ Brody Grant, "The Outsiders" ☐ Jonathan Groff, "Merrily We Roll Along" Dorian Harewood, "The Notebook" ☐ Brian d'Arcy James, "Days of Wine and Roses" ☐ Eddie Redmayne, "Cabaret" The New York Times 2024 Tony Awards Ballot Best Leading Actress in a Musical Eden Espinosa, "Lempicka" ☐ Maleah Joi Moon, "Hell's Kitchen" Kelli O'Hara, "Days of Wine and Roses" ☐ Maryann Plunkett, "The Notebook" ☐ Gayle Rankin, "Cabaret" Best Featured Actor in a Play ☐ Will Brill, “Stereophonic" Eli Gelb, "Stereophonic" ☐ Jim Parsons, "Mother Play" Tom Pecinka, "Stereophonic" Corey Stoll, "Appropriate" Best Featured Actor in a Musical ☐ Roger Bart, "Back to the Future" ☐ Joshua Boone, "The Outsiders" ☐ Brandon Victor Dixon, "Hell's Kitchen" ☐ Sky Lakota-Lynch, "The Outsiders" ☐ Daniel Radcliffe, "Merrily We Roll Along" ☐ Steven Skybell, "Cabaret" Best Featured Actress in a Play ☐ Quincy Tyler Bernstine, "Doubt" ☐ Juliana Canfield, ☐ "Stereophonic" Celia Keenan-Bolger, "Mother Play" Best Direction of a Musical ☐ Maria Friedman, ㅁㅁㅁ ㅁ "Merrily We Roll Along" Best Lighting Design of a Musical ☐ Brandon Stirling Baker, "Illinoise" Michael Greif, "Hell's Kitchen" ☐ Isabella Byrd, "Cabaret" Leigh Silverman, "Suffs" ☐ ☐ Jessica Stone, "Water for Elephants" ☐ Danya Taymor, "The Outsiders" Best Scenic Design of a Play Natasha Katz, "Hell's Kitchen" ☐ Bradley King and David Bengali, "Water for Elephants" ☐ Brian MacDevitt and Hana S. Kim, "The Outsiders" Best Sound Design dots, "An Enemy of the People" of a Play ☐ dots, "Appropriate" Derek McLane, "Purlie Victorious" David Zinn, "Jaja's African Hair Braiding" David Zinn, "Stereophonic" Best Scenic Design of a Musical ☐ AMP featuring Tatiana Kahvegian, "The Outsiders" ☐ Robert Brill and Peter Nigrini, "Hell's Kitchen" ☐ Tim Hatley and Finn Ross, "Back to the Future" ☐ Riccardo Hernández and Peter Nigrini, "Lempicka" ☐ Takeshi Kata, "Water for Elephants" David Korins, "Here Lies Love" ☐ Tom Scutt, "Cabaret" Best Costume Design of a Play ☐ Dede Ayite, "Appropriate" ☐ Dede Ayite, "Jaja's African Hair Braiding" ☐ Sarah Pidgeon, "Stereophonic" ☐ Enver Chakartash, ☐ Kara Young, "Purlie Victorious" Best Featured Actress in a Musical ☐ Shoshana Bean, "Hell's Kitchen" ☐ Amber Iman, "Lempicka" Nikki M. James, "Suffs" ☐ ☐ Leslie Rodriguez Kritzer, "Spamalot" Kecia Lewis, "Hell's Kitchen" ☐ Lindsay Mendez, "Merrily We Roll Along" ☐ Bebe Neuwirth, "Cabaret" Best Direction of a Play Daniel Aukin, "Stereophonic" ☐ Anne Kauffman, "Mary Jane" Kenny Leon, "Purlie Victorious" Lila Neugebauer, "Appropriate" Whitney White, ☐ ☐ ☐ ☐ ☐ "Jaja's African Hair Braiding" ☐ ☐ "Stereophonic" ☐ Justin Ellington and Stefania Bulbarella, "Jaja's African Hair Braiding" ☐ Leah Gelpe, "Mary Jane" ☐ Tom Gibbons, "Grey House" ☐ Bray Poor and Will Pickens, "Appropriate" ☐ Ryan Rumery, "Stereophonic" Best Sound Design of a Musical ☐ M.L. Dogg and Cody Spencer, "Here Lies Love" Kai Harada, "Merrily We Roll Along" ☐ Nick Lidster, "Cabaret" ☐ Gareth Owen, "Hell's Kitchen" ☐ Cody Spencer, "The Outsiders" Best Original Score Will Butler, "Stereophonic" ☐ Adam Guettel, "Days of Wine and Roses" ☐ Jamestown Revival and Justin Levine, "The Outsiders" ☐ David Byrne and Fatboy Slim, "Here Lies Love" ☐ Shaina Taub, "Suffs" Emilio Sosa, "Purlie Victorious" Best Choreography David Zinn, "An Enemy of the People" Best Costume Design of a Musical ☐ Dede Ayite, "Hell's Kitchen" ☐ Linda Cho, "The Great Gatsby" ☐ David Israel Reynoso, "Water for Elephants" Tom Scutt, "Cabaret" ☐ Paul Tazewell, "Suffs" Best Lighting Design of a Play ☐ Isabella Byrd, "An Enemy of the People" ☐ Amith Chandrashaker, "Prayer for the French Republic" Jiyoun Chang, “Stereophonic" Jane Cox, "Appropriate" ☐ Natasha Katz, "Grey House" ☐ Camille A. Brown, "Hell's Kitchen" ☐ Shana Carroll and Jesse Robb, "Water for Elephants" ☐ Rick and Jeff Kuperman, "The Outsiders" ☐ Annie-B Parson, "Here Lies Love" Justin Peck, "Illinoise" Best Orchestrations ☐ Timo Andres, "Illi

Persons: Mary Jane, Tommy, Bekah, Kristoffer Diaz, Rick Elice, ☐ Adam Rapp, Justin Levine, ☐ Shaina Taub, William Jackson Harper, Uncle Vanya, Leslie Odom Jr, ☐ Liev Schreiber, Jeremy Strong, Michael Stuhlbarg, Betsy Aidem, Jessica Lange, Rachel McAdams, Sarah Paulson, Amy Ryan, Brody Grant, Jonathan Groff, Dorian Harewood, Brian d'Arcy James, Eddie Redmayne, Eden Espinosa, Maleah Joi Moon, Kelli O'Hara, ☐ Maryann Plunkett, ☐ Gayle Rankin, Will Brill, Eli Gelb, Jim Parsons, Tom Pecinka, Corey Stoll, Roger Bart, Joshua Boone, ☐ Brandon Victor Dixon, Lynch, ☐ Daniel Radcliffe, Steven Skybell, Quincy Tyler Bernstine, Juliana Canfield, Celia Keenan, Bolger, Maria Friedman, ㅁㅁㅁ, Brandon Stirling Baker, Michael Greif, Isabella Byrd, Leigh Silverman, Jessica Stone, Natasha Katz, ☐ Bradley King, David Bengali, Brian MacDevitt, Hana S, Kim, Derek McLane, David Zinn, Tatiana Kahvegian, ☐ Robert Brill, Peter Nigrini, Tim Hatley, Finn Ross, Riccardo Hernández, Takeshi Kata, David Korins, Tom Scutt, Dede Ayite, Sarah Pidgeon, Enver Chakartash, ☐ Kara Young, Shoshana Bean, Amber Iman, Nikki M, James, ☐ Leslie Rodriguez Kritzer, Kecia Lewis, ☐ Lindsay Mendez, Bebe Neuwirth, Daniel Aukin, Anne Kauffman, Kenny Leon, Lila Neugebauer, White, Justin Ellington, Stefania Bulbarella, Leah Gelpe, ☐ Tom Gibbons, ☐ Bray, Will Pickens, Ryan Rumery, Cody Spencer, Kai Harada, Nick Lidster, ☐ Gareth Owen, ☐ Cody Spencer, Will Butler, Adam Guettel, ☐ David Byrne, Fatboy Slim, Shaina Taub, Emilio Sosa, Linda Cho, ☐ David Israel Reynoso, ☐ Paul Tazewell, Jiyoun Chang, Jane Cox, Camille A . Brown, ☐ Shana Carroll, Jesse Robb, Rick, Jeff Kuperman, Annie, Parson, Justin Peck, ☐ Timo Andres, Tom Kitt, Adam Blackstone, Justin Craig, Matt Hinkley, Jonathan Tunick Organizations: Patriots, New York Times, Lakota, ☐ Bray Poor Locations: Republic, Jamestown

☆ What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
▼ + stars: | 2024-05-13 | by ( Meg Tirrell | ) edition.cnn.com time to read: +10 min

CNN —New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use. A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo. It was sustained for up to four yearsThe results showed that the 10% average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years. Patients stayed on the medicine while they sustained the weight loss. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo.

Persons: Wegovy, –, ”, Harlan Krumholz, Dr, Donna Ryan, Eli Lilly, wasn’t, they’d, Daniel Drucker, it’s, John Deanfield, Krumholz, Drucker, GLP, Sanjay Gupta Organizations: CNN, Yale University, Yale New Haven Hospital, drugmaker, Nordisk, Novo Nordisk, European, Obesity, Nature, Pennington Biomedical Research, University of Toronto, University College London, CNN Health Locations: Baton Rouge , Louisiana, Novo

☆ Who Are Key Players in the Menendez Case?
▼ + stars: | 2024-05-11 | by ( Tracey Tully | Benjamin Weiser | ) www.nytimes.com time to read: +7 min

Who Are Key Players in the Menendez Case? Mr. Menendez goes to trial on May 13 with two of the businessmen, Fred Daibes and Wael Hana. Fred Daibes New Jersey Real Estate Developer Mr. Daibes is accused of giving Mr. Menendez furniture, gold and cash. Nadine Menendez Mr. Menendez’s Wife Ms. Menendez served as a go-between for Mr. Menendez, Egyptian intelligence officials and men who were seeking political favors from the senator, according to the indictment. Defense LawyersAdam Fee Lawyer for Robert Menendez He previously spent five years as a prosecutor in the U.S. attorney’s office for the Southern District — the same office prosecuting Mr. Menendez.

Persons: Menendez, Robert Menendez, Nadine Menendez, Mr, Fred Daibes, Wael Hana, Menendez's, Daibes, Nadine Menendez Mr, Menendez’s, Ms, Jose Uribe, Uribe, Uribe's, Sidney H, Stein, Bill Clinton, Jennifer Shah, Hassan Nemazee, Damian Williams, Williams, President Biden, Sam Bankman, Fried, Juan Orlando Hernández, Christina Clark, Clark, Charles McGonigal, Catherine Ghosh, Eli Mark, Paul Monteleoni, Robert Hadden, Lara Pomerantz, Ghislaine Maxwell, Jeffrey Epstein, Norman Seabrook, Daniel Richenthal, Sheldon Silver, Michael Avenatti, Adam Fee, Fee, Avi Weitzman, Lawrence Lustberg Organizations: Democrat, Robert Menendez New Jersey, Senate Foreign Relations, Jersey Real, EG, Prosecutors, United, Jose Uribe Former New, Benz, U.S, Southern, of, Democratic, Attorney, Southern District of, ex, Public, New, New York City Housing Authority, Justice Department, Southern District’s, New York State Assembly, Nike . Defense, Southern District Locations: New Jersey, Manhattan, Jersey, Egypt, Qatar, United States, Jose Uribe Former New Jersey, of New York, Southern District, Southern District of New York, Russian, New York City, Brooklyn, Columbia, New York, U.S, California

☆ ‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their safety if they do
▼ + stars: | 2024-05-08 | by ( Mira Cheng | Meg Tirrell | ) edition.cnn.com time to read: +12 min

“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.

Persons: CNN — Catera Bentley, Bentley, ”, “, ” Bentley, she’d, —, ‘, ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, —, Colorado

☆ Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
▼ + stars: | 2024-05-07 | by ( Eduardo Munoz | ) www.cnbc.com time to read: +3 min

A highly popular group of weight loss and diabetes drugs is still hard to find in the U.S. The dominant manufacturers of those treatments, Eli Lilly and Novo Nordisk , are making progress toward changing that. Patients using current autoinjectors for weight loss and diabetes drugs go through four different pens per month. Eli Lilly expects supply for Zepbound, Mounjaro and other incretin drugs to remain "quite tight" in the near- to mid-term as demand remains high, Ashkenazi said. On the day Eli Lilly reported earnings, shares of the company jumped more than 5% on the raised guidance and supply updates.

Persons: Eli Lilly, Anat Ashkenazi, There's, Ashkenazi, David Ricks, —, Lilly, Chris Schott Organizations: U.S, Novo Nordisk, Nexus Pharmaceuticals, JPMorgan Locations: North Carolina, Indiana, Ireland, Germany, Europe, U.S

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ What's driving this multiday rally, plus Jim Cramer's quick takes on 4 stocks
▼ + stars: | 2024-05-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stock gains continue: The market is higher on Monday, extending its gains over the past three sessions to nearly 3%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jerome Powell, overbought, Jim Cramer's, Jim, Mellody Hobson, Howard Schultz, Laxman Narasimhan, Eli Lilly, Amgen, Lilly, Christian Organizations: CNBC, Stock, Starbucks, Worldwide Developers Conference, VisionPro, Nvidia, pharma, FDA, Simon Property Group, Club, Rockwell Automation, Jim Cramer's Charitable, Apple, Getty Locations: WWDC, Hamburg, Germany

☆ Generative AI will be designing new drugs all on its own in the near future
▼ + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com time to read: +12 min

An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.

Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature

☆ Earnings will drive the market next week — what we expect from 2 portfolio stocks
▼ + stars: | 2024-05-04 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

With the Fed, Apple earnings and the jobs report passing with flying colors this week, the runway to more gains looks a lot less cluttered. This past week was chock full of Club earnings: 12 portfolio companies, including Apple , delivered results. Analysts expect Wynn's earnings per share of $1.27 versus 29 cents a year ago when China was not fully back from Covid. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jerome Powell, we're, Jim Cramer, Jim, Apple, Eli Lilly, Estee Lauder, Stanley Black, Decker, Bausch, FactSet, It's, Bob Iger, Iger, Nelson Peltz, We're, Krystal, Berkshire Hathaway, Tyson, Jones Lang, Walt, Ferrari N.V, WK Kellogg, Wynn, Vishay, CRON, MARA, RICK, Ginkgo, Jim Cramer's, David Paul Morris Organizations: Federal Reserve, Apple, GE Healthcare, DuPont, Linde, Bausch Health, Coterra Energy, Club, Disney, Wynn Resorts, CNBC, Revenue, Vegas Sands, Cotai, Boston, Airlines, Krystal Biotech, Alpha Metallurgical Resources, Axsome Therapeutics, Tyson Foods, TSN, Bowlero Corp, CNA Financial Corp, CNA, Jones Lang LaSalle Incorporated, Technologies, Realty Income Corp, Lab, Teradata Corp, Technology, FMC Corporation, FMC, Paymentus Holdings, Shockwave, Vertex Pharmaceuticals, Goodyear Tire & Rubber Company, Simon Property Group, Sterling Construction Company, Apple Hospitality, Boise Cascade Corporation, BellRing Brands, Coty, COTY, Fidelity National Information Services Inc, Vornado Realty, Walt Disney Co, Holdings, Madrigal Pharmaceuticals, Nikola Corporation, BP, Rockwell Automation, MarketAxess Holdings, Jumia Technologies, GEO Group, Builders FirstSource Inc, Duke Energy Corp, WYNN, Rivian Automotive, Arista Networks, Occidental Petroleum Corp, Astera Labs, Bros, Flywire Corporation, B2Gold Corp, Kinross Gold Corp, Virgin Galactic Holdings, iRobot Corp, Electronic Arts Inc, McKesson Corp, ACM Research, Avadel Pharmaceuticals, Toyota Motor Corp, Emerson Electric Co, Perion, Editas, Brink's Company, Sinclair Corporation, New Fortress Energy, Starwood Property Trust, Animal Health, ELAN, Farms, IM Cannabis Corp, Fox Corporation, Formula One, Icahn Enterprises, Teva Pharmaceutical Industries, Arm Holdings plc, ARM, AMC Entertainment Holdings, Trade, AppLovin Corporation, Sciences Corp, SolarEdge Technologies, Roblox Corporation, GigaCloud Technology Inc, Warner Bros ., Properties Trust, Growers, Constellation Energy Group, Cronos, Fiverr, Solar Inc, EPAM Systems, Cedar Fair Entertainment, Digital Holdings, RCI Hospitality Holdings, Akamai Technologies, Semiconductor, Insulet Corp, NuScale Power Corporation, Ginkgo Bioworks Holdings, Bloom Energy Corporation, Construction, AMC Networks, CRH Public Ltd . Company, Jim Cramer's Charitable, Allen, Co . Media, Technology Conference, Bloomberg, Getty Locations: China, Eaton, Amazon, Covid, Macao, Vegas, Sun Valley , Idaho

☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
▼ + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.

Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S

☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
▼ + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.

Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America

☆ Stocks making the biggest moves premarket: Apple, Amgen, Cloudflare and more
▼ + stars: | 2024-05-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Hershey — Shares of the chocolate confectionary maker added about 1% after Hershey posted a first-quarter earnings beat. Hershey's $3.25 billion revenue also beat the $3.11 billion consensus. Amgen — Shares soared 13% after the biotech firm posted a first-quarter earnings and revenue beat. Cloudflare — The stock continued to sink, plunging 12% after reporting weak full-year guidance, although Cloudflare posted a first-quarter earnings and revenue beat. However, Coinbase's first-quarter revenue of $1.64 billion beat the $1.34 billion consensus, according to LSEG.

Persons: Hershey, LSEG, Apple, Eli Lilly, Cloudflare, Expedia, Piper Sandler, Fortinet, FactSet, Jefferies, Coinbase's, Benjamin Nolan, — CNBC's Brian Evans, Michelle Fox, Hakyung Kim, Tanaya Macheel Organizations: Hershey —, Apple, Novo Nordisk, BMO Capital Markets, Revenue, Arista Networks, Arista, LSEG . Union Pacific, JPMorgan Locations: billings, LSEG, Stifel

☆ Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
▼ + stars: | 2024-05-03 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Read previewDanish drugmaker Novo Nordisk will lower prices of its weight loss drug Wegovy as it plans to raise sales volumes and navigate tough competition. Prices for the blockbuster drug fell in the first quarter. Sales of Wegovy more than doubled in the first quarter year-on-year, to 9.4 billion Danish crowns, or $1.3 billion, according to the company's earnings. They did not specify how much Novo plans to cut Wegovy's prices. AdvertisementThe Danish pharmaceutical maker, which also produces viral weight loss drug Ozempic, reported better-than-expected sales of 65 billion Danish crowns, or $9.4 billion, in the first quarter.

Persons: —, Karsten Munk Knudsen, Knudsen, Lars Fruergaard Jorgensen, Ozempic, Eli Lilly, Wegovy, Bernie Sanders, Goldman Sachs, Oprah Winfrey, Elon Musk, Charles Barkley Organizations: Service, Nordisk, Business Locations: Danish, Novo

☆ Stocks making the biggest moves midday: Apple, Expedia, Block, Live Nation and more
▼ + stars: | 2024-05-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in midday trading: Apple — The tech giant jumped more than 6% after announcing it would repurchase $110 billion in shares . That topped analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Block — The payment services provider added 1% after posting first-quarter results that beat analysts' expectations. Live Nation Entertainment — Shares jumped 9% on the back of better-than-expected first-quarter revenue. However, the company beat analysts' expectations for the first quarter.

Persons: LSEG, Piper Sandler, FactSet, Eli Lilly, Cloudflare, Jefferies, —, Alex Harring, Lisa Kailai Han, Michelle Fox, Pia Singh Organizations: Apple, Management, Wall Street, BMO Capital Markets, Expedia, Holdings, bullish Bank of America, Novo Nordisk, Arista Networks, Arista Locations: Thursday's, billings

☆ Here's what's driving Friday's stock action in Apple, Coterra and Eli Lilly
▼ + stars: | 2024-05-03 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is the kind of number you need that basically says the Fed is doing their job," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Coterra, naysayers, Eli Lilly, drugmaker Amgen, we're, Jim Cramer's, Jim Organizations: CNBC, Club, Apple, Coterra Energy, Mizuho Securities

☆ Amgen scraps experimental weight loss pill, moves forward with injection
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the last year. Investors are laser-focused on Amgen's pipeline of experimental weight loss treatments. Amgen's injectable treatment also appears to help patients keep weight off after they stop taking it based on some clinical trial data.

Persons: Amgen, Eli Lilly, Jay Bradner, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound Organizations: Novo Nordisk, Pfizer, Novo Nordisk's Locations: Amgen, Thousand Oaks , California, MariTide, Novo

ImageHERE’S WHAT’S HAPPENINGExxon Mobil strikes an agreement to win regulatory approval of its $60 billion megadeal. Elsewhere, shares in Shell were up after the producer reported $7.7 billion in adjusted quarterly earnings, beating analyst expectations. The U.S. imposes sanctions on Chinese companies over military support for Russia’s war effort. The Biden administration announced on Wednesday nearly 300 sanctions, including on more than a dozen Chinese businesses, aimed at disrupting Moscow’s full-scale invasion of Ukraine. The culprit: pressure on prices, amid growing competition from Eli Lilly’s Zepbound, supply constraints and scrutiny from lawmakers.

Persons: Scott Sheffield, Biden, Janet Yellen, Antony Blinken, Eli Lilly’s Zepbound, James Comer, Comer Organizations: Labor Department, Exxon Mobil, Natural Resources, Wall Street, Novo Nordisk, Republican, European Commission Locations: Shell, U.S, Ukraine, Danish, Kentucky, iRobot

☆ Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
▼ + stars: | 2024-05-02 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — putting embattled shares under pressure. BHC YTD mountain Bausch Health YTD Bottom line Along with quarterly results, Bausch Health reaffirmed forward guidance. While not necessarily expected to see a massive increase in adoption in the future like Lilly's GLP-1s, Xifaxan currently accounts for 41% of Bausch Health sales, excluding B+L. Breaking that down: $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Bausch, Eli Lilly, It's, Xifaxan, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Norwich Pharmaceuticals, Amneal Pharmaceuticals, Food and Drug Administration, Management, CNBC Locations: generics, Norwich

☆ Cartier tried to stop a man from buying $13,600 earrings for $13 after a website typo, but he got them anyway
▼ + stars: | 2024-05-02 | by ( Amanda Krause | ) www.businessinsider.com time to read: +3 min

Read previewRogelio Villarreal Jasso got extremely lucky when he found heavily discounted Cartier earrings online. On December 1, 2023, the Mexico native noticed an Instagram advertisement for gold-and-diamond Cartier earrings priced at 232 pesos, or about $13, he told Business Insider. AdvertisementThe Cartier earrings purchased by Rogelio Villarreal Jasso. After being contacted by the agency, Cartier seemingly took matters into its own hands and settled the issue by sending Jasso his order. "It is more important to be honorable than to have Cartier earrings," she wrote.

Persons: —, Rogelio Villarreal Jasso, Cartier, Jasso, Champagne, Lilly Téllez Organizations: Service, Business, Federal, The New York Times, The Times, Times Locations: Mexico, Cartier's Mexico

☆ Trade Tracker: Joe Terranova sells Eli Lilly
▼ + stars: | 2024-05-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Joe Terranova sells Eli LillyThe Investment Committee discusses the healthcare sector as Joe Terranova sells Eli Lilly in his JOET rebalance.

Persons: Joe Terranova, Eli Lilly

☆ A millennial couldn't afford the Mounjaro weight-loss drug so he started secretly working 2 remote jobs. He's on track to make $166,000 this year and says he's lost 45 pounds.
▼ + stars: | 2024-05-01 | by ( Jacob Zinkula | ) www.businessinsider.com time to read: +6 min

A millennial in California is secretly working a second remote job so he can afford weight-loss drugs. AdvertisementLast August, George decided he wanted to try to work a second remote job — and not tell his employers he was job juggling. He was able to afford Mounjaro and said he's dropped 45 pounds — from 220 lbs to 175 lbs — since he started taking it in October. AdvertisementAfter a roughly monthlong search, he started his second job and was able to afford Mounjaro. Are you working multiple remote jobs at the same time and willing to discuss details about your pay and schedule?

Persons: Zepbound, —, George, Eli Lilly, he's, George hasn't, it's Organizations: Service, FDA, Nordisk's Ozempic, Business Locations: California, Mounjaro

☆ Jim Cramer says GE Healthcare's unwarranted post-earnings plunge is a buying opportunity
▼ + stars: | 2024-04-30 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Jim Cramer has said repeatedly the Fed does not need to cut anytime soon. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Jerome Powell, Jim, Eli Lilly, Eaton, Lilly, We're, McDonald, —, Jeff Marks, Jim Cramer's Organizations: CNBC, Dow Jones, Nasdaq, Federal, Fed, GE Healthcare, Constellation Brands, Molson Coors, TAP, Modelo, Corona, Web Services, Microsoft, Starbucks, Jim Cramer's Charitable Locations: China, Will

Here are our thoughts on this season’s inadvertent (and possibly advertent) snubs, delightful (or mystifying) surprises and other notable anomalies. A melancholy morning for ‘Vanya.’Television stars are considered good box office but not always good Tony bait. This year’s crop, including Sarah Paulson, Jeremy Strong, Steve Carell and William Jackson Harper, complicates that wisdom. Spreading all that love helped take the show to Number One with a Bullet — the most nominated play in Broadway history. On the other hand, the superb ensemble casts of “Jaja’s African Hair Braiding” and “Illinoise” were skunked.

Persons: “, ‘ Vanya, ’, Tony, Sarah Paulson, Jeremy Strong, Steve Carell, William Jackson Harper, Paulson, Carell, Harper, Uncle Vanya, ”, Chekhov, David Adjmi’s, Tom Pecinka, Sarah Pidgeon, Juliana Canfield, Will Brill, Eli Gelb, Illinoise Organizations: Broadway, Lincoln Center Theater

☆ Stock market today: futures slip ahead of Amazon earnings and a key Fed update
▼ + stars: | 2024-04-30 | by ( Theron Mohamed | ) www.businessinsider.com time to read: +2 min

US stock futures retreated on Tuesday as Wall Street awaited key earnings reports and a Fed update. AdvertisementStocks drifted lower in premarket trading on Tuesday as investors held their breath for marquee earnings reports and a critical update from the Federal Reserve. "If that's the case, we could see a further meltdown in Fed rate cut expectations. The next stop is no rate cut in 2024, which would be a cold shower for the bulls," she added. "If the Fed expectations turn undesirably hawkish, we could see the equity rally stall," Ozkardeskaya said.

Persons: Eli Lilly, McDonald's, —, Jerome Powell, Ipek Ozkardeskaya, it's, undesirably, Ozkardeskaya Organizations: Starbucks, Service, Federal Reserve, Dow Jones Industrial, Nasdaq, Treasury, Swissquote Bank

☆ Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise Chen
▼ + stars: | 2024-04-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald managing director, joins 'Squawk Box' to discuss Eli Lilly's quarterly earnings results, weight loss drug demand, growth outlook, and more.

Persons: Eli Lilly, Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald, Eli

Search resuls for: "Eli Lilly

25 mentions found